rofecoxib : Related Words Words similar in meaning to rofecoxib
- rofecoxib«
- nonsteroidal anti-inflammatory drug«
- merck«
- vioxx«
- heart attack«
- study«
- drug«
- risk«
- naproxen«
- relative risk«
- cox-2 inhibitor«
- fda«
- approve study«
- patient«
- vigor«
- nsaid«
- additional heart attack«
- aspirin«
- vigor study«
- cardiovascular risk«
- plaintiff«
- editorial«
- jury«
- adverse cardiovascular event«
- placebo«
- jüni«
- dose vioxx usage«
- celecoxib«
- new england journal«
- vioxx litigation«
- data«
- etoricoxib«
- cardiovascular safety«
- valdecoxib«
- pmid«
- trial«
- market«
- myocardial infarction«
- cox-2«
- stroke«
- cardiovascular event«
- vioxx gi outcome research«
- rofecoxib patient«
- prostaglandin responsible«
- prespecified cutoff date«
- mr mcdarby«
- merck liable«
- increased relative risk«
- arcoxia«
- martin report«
- lumiracoxib«
- coxib«
- efficacy«
- robert ernst«
- parecoxib«
- author«
- adverse effect profile«
- selective cox-2 inhibitor«
- al«
- bextra«
- humeston«
- celebrex«
- evidence«
- lancet«
- cox-1«
- month«
- nejm«
- warning«
- engl j med«
- heart disease«
- finding«
- difference«
- cyclooxygenase«
- acute pain«
- deposition«
- tort reform«
- protective effect«
- garza«
- prostaglandin«
- additional data«
- inflammatory drug«
- reuben«
- article«
- cutoff«
- withdrawal«
- dosage«
- scientific american«
- american medical association«
- report«
- co.«
- others«
- editor«
- whelton aa«
- week sample«
- vioxx. press release«
- vioxx warning label«
- vioxx usage«
- vioxx study result«
- vioxx study«
- vioxx sale«
- vioxx safety risk«
- vioxx multidistrict litigation«
- vigor article«
- vascular tone regulation«
- topol ej.«
- thomas cona«
- texas bring fewer suit«
- swan sk«
- superior gastrointestinal adverse effect profile«
- sterchi r«
- specific cox-2 inhibitor«
- significant 4-fold«
- secondary cardiovascular event«
- scientific misconduct trial«
- s. e. nissen«
- rofecoxib user«
- rofecoxib usage«
- rofecoxib therapy«
- renowned research cardiologist eric topol«
- reichenbach s«
- punitive damage limit«
- publishing controversy«
- protective effect similar«
- prostaglandin i2/pgi2/prostacyclin«
- prostacyclin/thromboxane«
- prostacyclin production«
- prostacyclin level«
- prominent merck critic«
- premenstrual acne vulgaris«
- platelet aggregation property«
- placebo population«
- phil fontanarosa«
- pfizer ’s celecoxib«
- parlow jl«
- other studies«
- other nsaids«
- other cox-2 inhibitors«
- nussmeier na«
- nejm editorial board«
- nejm editor gregory curfman«
- nartey l«
- naproxen treatment«
- naproxen population«
- naproxen patient«
- naproxen hypothesis«
- naproxen due«
- mild myocardial infarction«
- merck response«
- merck memo«
- merck author«
- merck announces voluntary worldwide withdrawal«
- marketing celecoxib«
- mar 31;352(13):1283«
- lower payouts«
- leleti rajender reddy«
- lax editing«
- langford rm«
- karha j«
- kaiser permanente data«
- jüni p«
- journal staffer hour«
- imminent presentation«
- hoeft a«
- grassley ce«
- fitzgerald ga«
- federal vioxx trial«
- fda memorandum«
- fda analyst«
- executive editor gregory curfman«
- elevated death rate«
- egger m«
- edgar lee boyd«
- e. j. topol«
- drug manufacturer merck«
- dr. curfman«
- dose aspirin prophylaxis«
- dieppe pa«
- debilitating peptic ulcer«
- d. m. mukherjee«
- coxib meeting«
- cox-2 inhibitiors«
- corey ej. facile air oxidation«
- cleve clin j med«
- chronic human toxicity tetrahedron lett«
- ceoxx«
- ceeoxx«
- carol ernst«
- cardiovascular safety database«
- cardiovascular event associated«
- brown mt«
- brand name vioxx«
- author month«
- arthritis advisory committee«
- arrhythmia pathology«
- approximate bioavailability«
- anflamattory drug«
- adverse thrombotic cardiovascular event«
- adenomatous polyp prevention«
- effect«
- significant difference«
- scientist«
- your promotional campaign discount«
- wrongful death trial«
- vioxx labeling«
- summary minute«
- reserve charge«
- reported benefit«
- prothrombotic effect«
- nejms«
- late night email«
- elevated cardiovascular risk«
- elderly canadian«
- efficacy studies«
- dr. topol«
- dihydro derivative«
- december trial«
- cyclooxygenase-2 inhibition«
- conventional nsaid«
- acute pain condition«
- information«
- safety«
- clinical trial«
- similar adverse effect profile«
- separate criminal proceeding«
- scott s. reuben«
- prexige«
- nejm editor«
- negative cardiovascular effect«
- int med«
- heart risk«
- gastrointestinal adverse event«
- cardiovascular mortality rate«
- cardiovascular event rate«
- Vioxx«
- Cox-2 inhibitor«
- 8-fold increase«
- 116,000+ participant«
- Celebrex«
- Bextra«
Sharpen your Skills with the Masters
The Life-Changing Magic of Tidying Up: The Japanese Art of Decluttering and Organizing
Rise of the Rocket Girls: The Women Who Propelled Us, from Missiles to the Moon to Mars
My Grandmother Asked Me to Tell You She's Sorry
The Only Grammar Book You'll Ever Need: A One-Stop Source for Every Writing Assignment